We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Japanese subsidiary of Swiss drug major Novartis is hoping to
boost its local market share to more than 4 percent by 2007, compared to the
2.7 percent share recorded for 2000.
Controversy over India's new patent regime continues, with
both multinationals and generic drugmakers voicing concerns, albeit for very
different reasons.
Israeli generics major Teva and US-based biotechnology firm Savient
have reached a partial agreement on their intellectual property disputes over
human growth hormone with Danish producer Novo Nordisk.
A former Commissioner for the Internal Market, Frits Bolkestein,
has urged that the European Union (EU)-wide ban on the advertising of prescription
pharmaceuticals be lifted.
Oxford Biomedica, a biotechnology spin-off company of the UK's Oxford
University, has licensed its LentiVector gene delivery system to a large unnamed
drug company.
Pfizer Ltd., the Indian affiliate of the US-based drug major, is
to turn its facility in Turbhe, Mumbai, into a leading R&D hub for animal
healthcare products.